Abstract
The TENDER clinical trial is a three-part, 5-year, phase 3 study with tocilizumab (TCZ) in active systemic JIA (sjia). After 2 years of treatments, sjia patients who have maintained clinically inactive disease for 3 months are given the option to participate in an alternative TCZ dosing regimen aimed at spacing the infusions and eventually withdrawing TCZ.
Highlights
The TENDER clinical trial is a three-part, 5-year, phase 3 study with tocilizumab (TCZ) in active systemic JIA
To qualify for the optional alternative dosing schedule (OADS), patients had to be in the study for 2 years and have achieved ACR JIA inactive disease status
Among the 112 patients enrolled, 39 (35%) entered the optional alternative dosing regimen
Summary
The TENDER clinical trial is a three-part, 5-year, phase 3 study with tocilizumab (TCZ) in active systemic JIA (sjia). After 2 years of treatments, sjia patients who have maintained clinically inactive disease for 3 months are given the option to participate in an alternative TCZ dosing regimen aimed at spacing the infusions and eventually withdrawing TCZ
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
